Published Date: 02 Mar 2023
In people with type 1 diabetes, the immune system attacks and destroys insulin. The cells that control blood sugar and are part of the cells of the pancreas are called islets. Looking for...
Read Full NewsNew data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.
Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.
Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.
High Rates of Overactive Bladder Found in Women With Fibromyalgia
Advanced Cardiovascular-Kidney-Metabolic Syndrome Increases Sarcopenia Risk
FDA Grants Breakthrough Device Designation to Holly Implantable Dialysis System
1.
Study finds that AI is better at forecasting the risk of developing cancer.
2.
Pickleball program boosts health and wellness for cancer survivors, study finds
3.
In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.
4.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
5.
Childhood cancer survivors face new health problems later in life, study shows
1.
Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access
2.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
3.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
4.
Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery
5.
Unlocking the Mystery of Ovarian Cancer Staging
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
5.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation